
WHAT IS CLAIMED IS:

1. A method for *ex vivo* activation of antigen-specific T cells, comprising: treating a population of antigen presenting cells ("APCs") with a bromodomain inhibitor; and adding a population of T cells to the population of treated APCs, wherein the bromodomain inhibitor comprises the following chemical formula:



.

2. The method of claim 1, wherein the APCs comprise dendritic cells or macrophages.

3. The method of claim 1 or 2, wherein the T lymphocytes are selected from the group consisting of autologous tumor-infiltrating lymphocytes (TIL), T cells transduced with high-affinity T cell receptors (TCR), and T cells transduced with chimeric antigen receptors (CAR).